ReviewCurrent treatment options in oncology2026
Management of Peptide Receptor Radionuclide Therapy Toxicities in Neuroendocrine Neoplasm Patients.
Review in Current treatment options in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comprehensive Somatic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms.Endocrine oncology (Bristol, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
opinion statementPeptide receptor radionuclide therapy (PRRT) has become an established treatment for patients with well-differentiated gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) that express somatostatin receptors. Among the available agents, lutetium-177 DOTATATE is the most commonly used radiolabeled somatostatin analog and has demonstrated significant clinical benefits, including improved response rates and prolonged progression-free survival, as shown in landmark trials such as NETTER-1 and NETTER-2. As the incidence of GEP-NENs continues to rise, the use of PRRT in clinical practice has grown accordingly. However, this therapy is associated with a range of toxicities that can affect multiple organ systems over different timeframes, including acute, subacute, and long-term periods. This review provides a comprehensive overview of the adverse effects associated with PRRT and presents evidence-based strategies for their monitoring, prevention, and management. This review also discusses the evolving paradigm of screening for clonal hematopoiesis before PRRT treatment, as well as the use of steroids as prophylaxis to prevent carcinoid crisis and bowel obstruction. A multidisciplinary approach is essential to ensure the safe delivery of treatment, early detection of complications, and tailored patient care. As clinical experience with PRRT expands, continued refinement of supportive care strategies will be critical to optimizing outcomes and minimizing toxicity in this complex patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.